Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments

Description: Excess Reinsurance is a coverage purchased by insurance carriers to limit loss in a year from any one claim. This article addresses the issues when purchasing medical excess reinsurance on a medical portfolio. The most important consideration in the reinsurance purchasing decision is determining the risk objectives of the organization. The proper risk analysis by the carrier or in conjunction with its reinsurer will address the following questions: What is predictable risk versus unpredictable risk?

Description: A comparison of fully insured medical insurance to two self- funding alternatives , specific and aggregate and level funding .

Description: Uses Monte Carol simulation to discuss increase in aggregate stop loss claim frequencies due to changes in selling strategies, August 2000, Issue No. 38.

Description: First dollar carriers, stop loss carriers, and reinsurers play a different role in reimbursing healthcare claims. This article explores the reinsurer's role in reimbursing COVID-19 related claims.

Description: Feature article discussing the American Academy of Actuaries Academy review of the various risk-based capital RBC formulas for health insurance products.

Description: November 2015 Reinsurance News

Description: September 2015 Reinsurance News

Description: The impact of benefit design on the cost of Aggregate Stop-Loss Coverage. Issue No. 42.

Description: A proposal to address provider payment issues by gradually moving to accountable care organizations. Capitations would be risk-adjusted, non-capitated costs would be covered by hospitalization fund and stoploss, incentives for quality & effective preventive care would be tied to the amount remaining in the fund, and government involvement would be through incentives rather than mandate.